Coya Therapeutics (COYA)

Executive Summary

Coya Therapeutics is a clinical-stage biotechnology company pioneering regulatory T cell (Treg)-enhancing therapies for neurodegenerative, autoimmune, and metabolic diseases. Its multi-modality platform comprises Treg-enhancing biologics (COYA 301/302), allogeneic Treg-derived exosomes (COYA 201), and autologous Treg cell therapy (COYA 101). The company is publicly traded on NASDAQ under ticker COYA and is headquartered in Houston, Texas. Coya's approach aims to modulate the immune system by boosting Treg function, addressing the underlying inflammation and immune dysregulation common in diseases like ALS, Alzheimer's, and type 1 diabetes. The platform's versatility positions Coya to potentially treat multiple high-unmet-need indications with a single mechanism. Coya's lead program, COYA 302, is in a Phase 2 trial (NCT07161999) for amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease with limited treatment options. The trial began enrollment in October 2025 and is expected to complete by July 2027. Interim data, if any, could provide early signals of efficacy. While the ALS program is high-risk due to historical trial failures, the Treg-enhancing strategy offers a novel approach that could differentiate COYA 302 if successful. Additionally, the company's pipeline includes preclinical and early-stage assets that may yield catalysts over the next 12-18 months. Given the early stage and high risk, but innovative platform and significant unmet need, Coya presents a speculative opportunity for investors willing to accept high volatility.

Upcoming Catalysts (preview)

• Q1 2027Interim data from Phase 2 trial of COYA 302 in ALS40% success
• H2 2026Initiation of Phase 2 trial for COYA 302 in Alzheimer's disease or autoimmune indication50% success
• Q1 2027Regulatory update or IND filing for COYA 201 (exosome) or COYA 101 (cell therapy) program50% success